![](https://epigen.concytep.gob.mx/wp-content/uploads/2023/08/mockup-articulo-dra-karla-1-1024x724.jpg)
Karla Rubio, Alejandro Molina-Herrera, Andrea Pérez-González,Hury Viridiana Hernández-Galdámez, Carolina Piña-Vázquez, Tania Araujo-Ramos and Indrabahadur Singh
EP300 as a Molecular Integrator of Fibrotic Transcriptional Programs cancer
Abstract:
Fibrosisis a condition characterized by the excessive accumulation of extra cellular matrix proteins in tissues, leading to organ dysfunction and failure. Recen tstudies have identi?ed EP300 ,a histone acetyltransferase, as a crucia lregulator of the epigenetic changes that contribute to ?brosis. Infact, EP300-mediated acetylation of histones alters global chromatin structure and gene expression, promoting the development and progression of ?brosis. Here, were view the role of EP300-mediated epigenetic regulation inmulti-organ ?brosis and its potential as a therapeutic target. We discuss the preclinical evidence that suggests that EP300 in hibition can attenuate ?brosis-related molecular processes, including extra cellular matrix deposition, in?ammation, and epithelial-to-mesenchymal transition. We also highlight the contributions of small molecule in hibitors and gene therapy approaches targeting EP300 as novel therapies against ?brosis.